Get the Stockscreener App
13.98
3.19%
-0.46
Prothena Corporation Plc stock is traded at $13.98, with a volume of 120.30K.
It is down -3.19% in the last 24 hours and down -1.20% over the past month.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
See More
Previous Close:
$14.44
Open:
$14.55
24h Volume:
120.30K
Relative Volume:
0.24
Market Cap:
$776.47M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-13.98
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
-1.76%
1M Performance:
-1.20%
6M Performance:
-27.41%
1Y Performance:
-47.46%
1-Day Range:
$13.86
$14.75
1-Week Range:
$13.20
$15.09
52-Week Range:
$11.70
$31.03
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
14.00 | 776.47M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.37 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings) - Benzinga
Metric Analysis: Prothena Corporation plc (PRTA)’s Key Ratios in the Limelight - The Dwinnex
Q2 Earnings Forecast for Prothena Issued By Zacks Research - MarketBeat
Prothena (NASDAQ:PRTA) Stock Price Down 4.8%Here's What Happened - MarketBeat
SG Americas Securities LLC Increases Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Equities Analysts Offer Predictions for Prothena Q2 Earnings - Defense World
Brokerages Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $46.50 - Defense World
Duncan Williams Asset Management LLC Has $958,000 Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $46.50 Consensus PT from Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Trading 6.7% HigherHere's Why - MarketBeat
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price - Simply Wall St
Cantor Fitzgerald Predicts Prothena FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Prothena FY2025 Earnings - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
JPMorgan Chase & Co. Has $3.35 Million Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Hennion & Walsh Asset Management Inc. Takes $724,000 Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena (NASDAQ:PRTA) Shares Up 6.8%Time to Buy? - MarketBeat
Trading (PRTA) With Integrated Risk Controls - Stock Traders Daily
AL Amyloidosis Pipeline Analysis 2024: FDA Approvals, Emerging - openPR
Barclays PLC Grows Stock Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Purchased by Barclays PLC - Defense World
Prothena (NASDAQ:PRTA) Stock Price Down 9%Here's What Happened - MarketBeat
Prothena (NASDAQ:PRTA) Trading Up 6.5%What's Next? - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Receives $52.29 Average Price Target from Analysts - Defense World
Prothena Corporation plc (NASDAQ: PRTA) Down -6.92%: Here’s What Analysts’ Predictions Are Now. - Stocks Register
Brokerages Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $52.29 - MarketBeat
Prothena (NASDAQ:PRTA) Trading Down 2.6%Time to Sell? - MarketBeat
Prothena Corporation PLC (NASDAQ:PRTA) Director Oleg Nodelman Resigns - Defense World
Prothena Director Oleg Nodelman Steps Down After 5-Year Tenure, Ahead of Major 2025 Clinical Milestones - StockTitan
Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Geode Capital Management LLC - Defense World
Prothena Co. plc (NASDAQ:PRTA) Shares Bought by Barclays PLC - Defense World
Barclays PLC Buys 49,916 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
How the (PRTA) price action is used to our Advantage - Stock Traders Daily
We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate - Yahoo Finance
Prothena Co. plc (NASDAQ:PRTA) Position Trimmed by State Street Corp - Defense World
Prothena Co. plc (NASDAQ:PRTA) Holdings Decreased by State Street Corp - MarketBeat
Prothena Surges After Parkinson's Drug Misses Primary Endpoint - Seeking Alpha
Prothena (NASDAQ:PRTA) Earns Buy Rating from HC Wainwright - MarketBeat
Prothena (NASDAQ:PRTA) Coverage Initiated at Chardan Capital - MarketBeat
Demystifying Prothena Corp: Insights From 6 Analyst Reviews - Benzinga
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years - Simply Wall St
Prothena Corp (NASDAQ:PRTA) Stock Quotes, Forecast and News Summary - Benzinga
Prothena Shares Surge 43% Despite Setback in Parkinson's Drug Trial, Investors Eye Future Potential - mediahousepress
Prothena stock soars despite study miss By Investing.com - Investing.com Canada
Prothena stock soars despite study miss - Investing.com
Prothena (NASDAQ:PRTA) Price Target Cut to $22.00 by Analysts at Bank of America - MarketBeat
Why Is Prothena Corp Stock Soaring Today?Roche Holding (OTC:RHHBY) - Benzinga
Prothena shares price target cut after Parkinson's study miss By Investing.com - Investing.com UK
Prothena stock gains despite Parkinson’s setback (RHHBY:OTCQX) - Seeking Alpha
Prothena’s Parkinson’s study fails primary endpoint despite some success - Yahoo Finance
Prothena (NASDAQ:PRTA) Hits New 52-Week LowHere's Why - MarketBeat
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):